Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zura Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zura Bio's regulatory disclosures and financial reporting.
Zura Bio Limited (Nasdaq: ZURA) filed an 8-K announcing a leadership transition in its finance organization. The Board has appointed Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. Hyllengren brings more than two decades of biotech experience, most recently serving as CFO/COO of Atara Biotherapeutics and holding multiple senior finance roles at Amgen. His compensation package includes a $475,000 base salary, a target bonus equal to 40 % of salary, and an inducement option for 672,000 Class A shares that vests over four years.
Current CFO Verender Badial tendered his resignation on June 25, 2025. He will stay through the effective date and remain as a non-executive employee until July 31, 2025 to ensure continuity. A Settlement Agreement provides Badial with cash severance and benefits totaling roughly £295,000, accelerated vesting on options covering 186,561 shares, transfer restrictions on those shares for up to three years, and an extension of option exercise periods. Options for 303,100 shares granted on May 8, 2025 will be forfeited.
Key implications for investors:
- The company gains an experienced biotech finance executive with M&A, operations and capital-markets expertise.
- Management states the transition is not related to accounting disagreements, reducing concern over financial reporting integrity.
- Severance and inducement equity create modest near-term cash outflow and long-term dilution, but no immediate impact on operating results.
A press release dated July 1, 2025 regarding these changes was furnished as Exhibit 99.1.